** Shares of eye-disease focused Eyenovia EYEN.O fall 2.4% to $1.63 premarket
** Co says it is exploring a reverse merger with privately held Betaliq to combine their eye-disease focused operations
** The proposed deal values Betaliq at around $77 million and Eyenovia at about $15 million
** EYEN will hold 16.3% of the combined company and Betaliq will hold the remaining stake, if merger is successful
** Both EYEN's Optejet device and Betaliq's EyeSol technology are used to deliver FDA-approved eye-care medications to patients
** Up to last close, EYEN fell ~2x in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。